Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Prenatal DNA Sequencing Market by APPLICATION (Hemophilia, Down Syndrome, Cystic Fibrosis, Autism, DiGeorge Syndrome, AIDS, Cancer, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A00445

Pages: NA

Charts: NA

Tables: NA

DNA sequencing is a process used to determine the order of nucleotides within DNA molecules. Prenatal DNA sequencing is the method of sequencing the DNA isolated from pregnant women’s blood to reveal the full genetic code of a fetus. Prenatal DNA sequencing is used to sequence the whole genome of unborn baby that effectively detects the diseases or disorder such as Down syndrome, cystic fibrosis, thalassemia and cancer. The wide acceptance and adoption of prenatal DNA sequencing technology would have huge impact on  public health care sector . The potential application of sequencing technology is growing immensely.. Based on this sequencing technology, several laboratories and companies have launched diagnostic  test. Wide use and effective application of prenatal DNA sequencing increased the demand for sequencing instruments and reagents market. However, it requires huge amount for repetitive sequencing that makes it too expensive for routine use. Companies such as Illumina charge $9,500 to sequence the genome of an adult and fetal DNA sequencing, on the other hand costs much higher. 

The prenatal DNA sequencing market is segmented based on the application and geography. Prenatal DNA sequencing techniques are used to detect the diseases such as Hemophilia Down Syndrome, Cystic Fibrosis, Autism, DiGeorge Syndrome, AIDS and Cancer. Geographically, the prenatal DNA sequencing market is segmented into North America, Asia Pacific, Europe, and LAMEA .

KEY BENEFITS 

  • In-depth analysis of various regions would provide a clear understanding of current and future trends so that companies can make region specific plans
  • Comprehensive analysis of the factors that drive and restrict the growth of the prenatal DNA sequencing market is provided
  • Key regulatory guidelines in various regions, which impact the prenatal DNA sequencing market are critically examined 
  • Quantitative analysis of the current market and estimations are provided to showcase the financial calibre of the prenatal DNA sequencing market
  • Deep dive analysis of various regions provides insights that would enable companies to plan their business moves strategically
  • Value chain analysis in the report gives a clear understanding of the roles of the stakeholders involved in the supply chain of the prenatal DNA sequencing market

 Key Market Segments

  • By APPLICATION
    • Hemophilia
    • Down Syndrome
    • Cystic Fibrosis
    • Autism
    • DiGeorge Syndrome
    • AIDS
    • Cancer
    • Others
  • By GEOGRAPHY
    • North America
    • Europe
    • Asia-Pacific
    • LAMEA

 
Key Market Players

  • Illumina
  • BGI
  • Qiagen
  • Roche
  • NeuAnalytica Corp
  • Thermo Fisher Scientific Inc.
  • PerkinElmer
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California
  • Agilent Technologies

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PRENATAL DNA SEQUENCING MARKET, BY APPLICATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Application

    • 4.2. Hemophilia

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Down Syndrome

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Cystic Fibrosis

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Autism

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. DiGeorge Syndrome

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. AIDS

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Cancer

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Others

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

  • CHAPTER 5: PRENATAL DNA SEQUENCING MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Application

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Prenatal Dna Sequencing Market

        • 5.2.4.1. Market Size and Forecast, By Application

      • 5.2.5. Canada Prenatal Dna Sequencing Market

        • 5.2.5.1. Market Size and Forecast, By Application

      • 5.2.6. Mexico Prenatal Dna Sequencing Market

        • 5.2.6.1. Market Size and Forecast, By Application

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Application

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Prenatal Dna Sequencing Market

        • 5.3.4.1. Market Size and Forecast, By Application

      • 5.3.5. Germany Prenatal Dna Sequencing Market

        • 5.3.5.1. Market Size and Forecast, By Application

      • 5.3.6. Italy Prenatal Dna Sequencing Market

        • 5.3.6.1. Market Size and Forecast, By Application

      • 5.3.7. Spain Prenatal Dna Sequencing Market

        • 5.3.7.1. Market Size and Forecast, By Application

      • 5.3.8. UK Prenatal Dna Sequencing Market

        • 5.3.8.1. Market Size and Forecast, By Application

      • 5.3.9. Russia Prenatal Dna Sequencing Market

        • 5.3.9.1. Market Size and Forecast, By Application

      • 5.3.10. Rest Of Europe Prenatal Dna Sequencing Market

        • 5.3.10.1. Market Size and Forecast, By Application

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Application

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Prenatal Dna Sequencing Market

        • 5.4.4.1. Market Size and Forecast, By Application

      • 5.4.5. Japan Prenatal Dna Sequencing Market

        • 5.4.5.1. Market Size and Forecast, By Application

      • 5.4.6. India Prenatal Dna Sequencing Market

        • 5.4.6.1. Market Size and Forecast, By Application

      • 5.4.7. South Korea Prenatal Dna Sequencing Market

        • 5.4.7.1. Market Size and Forecast, By Application

      • 5.4.8. Australia Prenatal Dna Sequencing Market

        • 5.4.8.1. Market Size and Forecast, By Application

      • 5.4.9. Thailand Prenatal Dna Sequencing Market

        • 5.4.9.1. Market Size and Forecast, By Application

      • 5.4.10. Malaysia Prenatal Dna Sequencing Market

        • 5.4.10.1. Market Size and Forecast, By Application

      • 5.4.11. Indonesia Prenatal Dna Sequencing Market

        • 5.4.11.1. Market Size and Forecast, By Application

      • 5.4.12. Rest of Asia Pacific Prenatal Dna Sequencing Market

        • 5.4.12.1. Market Size and Forecast, By Application

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Application

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Prenatal Dna Sequencing Market

        • 5.5.4.1. Market Size and Forecast, By Application

      • 5.5.5. South Africa Prenatal Dna Sequencing Market

        • 5.5.5.1. Market Size and Forecast, By Application

      • 5.5.6. Saudi Arabia Prenatal Dna Sequencing Market

        • 5.5.6.1. Market Size and Forecast, By Application

      • 5.5.7. UAE Prenatal Dna Sequencing Market

        • 5.5.7.1. Market Size and Forecast, By Application

      • 5.5.8. Argentina Prenatal Dna Sequencing Market

        • 5.5.8.1. Market Size and Forecast, By Application

      • 5.5.9. Rest of LAMEA Prenatal Dna Sequencing Market

        • 5.5.9.1. Market Size and Forecast, By Application

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning, 2024

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. Illumina

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. BGI

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Oxford Nanopore Technologies

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. PerkinElmer

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

    • 7.5. Qiagen

      • 7.5.1. Company Overview

      • 7.5.2. Key Executives

      • 7.5.3. Company Snapshot

      • 7.5.4. Operating Business Segments

      • 7.5.5. Product Portfolio

      • 7.5.6. Business Performance

      • 7.5.7. Key Strategic Moves and Developments

    • 7.6. Thermo Fisher Scientific Inc.

      • 7.6.1. Company Overview

      • 7.6.2. Key Executives

      • 7.6.3. Company Snapshot

      • 7.6.4. Operating Business Segments

      • 7.6.5. Product Portfolio

      • 7.6.6. Business Performance

      • 7.6.7. Key Strategic Moves and Developments

    • 7.7. Agilent Technologies

      • 7.7.1. Company Overview

      • 7.7.2. Key Executives

      • 7.7.3. Company Snapshot

      • 7.7.4. Operating Business Segments

      • 7.7.5. Product Portfolio

      • 7.7.6. Business Performance

      • 7.7.7. Key Strategic Moves and Developments

    • 7.8. Pacific Biosciences Of California

      • 7.8.1. Company Overview

      • 7.8.2. Key Executives

      • 7.8.3. Company Snapshot

      • 7.8.4. Operating Business Segments

      • 7.8.5. Product Portfolio

      • 7.8.6. Business Performance

      • 7.8.7. Key Strategic Moves and Developments

    • 7.9. Roche

      • 7.9.1. Company Overview

      • 7.9.2. Key Executives

      • 7.9.3. Company Snapshot

      • 7.9.4. Operating Business Segments

      • 7.9.5. Product Portfolio

      • 7.9.6. Business Performance

      • 7.9.7. Key Strategic Moves and Developments

    • 7.10. NeuAnalytica Corp

      • 7.10.1. Company Overview

      • 7.10.2. Key Executives

      • 7.10.3. Company Snapshot

      • 7.10.4. Operating Business Segments

      • 7.10.5. Product Portfolio

      • 7.10.6. Business Performance

      • 7.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PRENATAL DNA SEQUENCING MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PRENATAL DNA SEQUENCING MARKET FOR HEMOPHILIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PRENATAL DNA SEQUENCING MARKET FOR DOWN SYNDROME, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PRENATAL DNA SEQUENCING MARKET FOR CYSTIC FIBROSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL PRENATAL DNA SEQUENCING MARKET FOR AUTISM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL PRENATAL DNA SEQUENCING MARKET FOR DIGEORGE SYNDROME, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL PRENATAL DNA SEQUENCING MARKET FOR AIDS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL PRENATAL DNA SEQUENCING MARKET FOR CANCER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL PRENATAL DNA SEQUENCING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL PRENATAL DNA SEQUENCING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA PRENATAL DNA SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 13. U.S. PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 14. CANADA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 15. MEXICO PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 16. EUROPE PRENATAL DNA SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. EUROPE PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 18. FRANCE PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. GERMANY PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 20. ITALY PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 21. SPAIN PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. UK PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 23. RUSSIA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. REST OF EUROPE PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. ASIA-PACIFIC PRENATAL DNA SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 26. ASIA-PACIFIC PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 27. CHINA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. JAPAN PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. INDIA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. SOUTH KOREA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 31. AUSTRALIA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. THAILAND PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. MALAYSIA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. INDONESIA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. REST OF ASIA PACIFIC PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. LAMEA PRENATAL DNA SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. LAMEA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. BRAZIL PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. SOUTH AFRICA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 40. SAUDI ARABIA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. UAE PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 42. ARGENTINA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. REST OF LAMEA PRENATAL DNA SEQUENCING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. ILLUMINA: KEY EXECUTIVES
  • TABLE 45. ILLUMINA: COMPANY SNAPSHOT
  • TABLE 46. ILLUMINA: OPERATING SEGMENTS
  • TABLE 47. ILLUMINA: PRODUCT PORTFOLIO
  • TABLE 48. ILLUMINA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 49. BGI: KEY EXECUTIVES
  • TABLE 50. BGI: COMPANY SNAPSHOT
  • TABLE 51. BGI: OPERATING SEGMENTS
  • TABLE 52. BGI: PRODUCT PORTFOLIO
  • TABLE 53. BGI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 54. OXFORD NANOPORE TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 55. OXFORD NANOPORE TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 56. OXFORD NANOPORE TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 57. OXFORD NANOPORE TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 58. OXFORD NANOPORE TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 59. PERKINELMER: KEY EXECUTIVES
  • TABLE 60. PERKINELMER: COMPANY SNAPSHOT
  • TABLE 61. PERKINELMER: OPERATING SEGMENTS
  • TABLE 62. PERKINELMER: PRODUCT PORTFOLIO
  • TABLE 63. PERKINELMER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 64. QIAGEN: KEY EXECUTIVES
  • TABLE 65. QIAGEN: COMPANY SNAPSHOT
  • TABLE 66. QIAGEN: OPERATING SEGMENTS
  • TABLE 67. QIAGEN: PRODUCT PORTFOLIO
  • TABLE 68. QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 69. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 70. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 71. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 72. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 73. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 74. AGILENT TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 75. AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 76. AGILENT TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 77. AGILENT TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 78. AGILENT TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. PACIFIC BIOSCIENCES OF CALIFORNIA: KEY EXECUTIVES
  • TABLE 80. PACIFIC BIOSCIENCES OF CALIFORNIA: COMPANY SNAPSHOT
  • TABLE 81. PACIFIC BIOSCIENCES OF CALIFORNIA: OPERATING SEGMENTS
  • TABLE 82. PACIFIC BIOSCIENCES OF CALIFORNIA: PRODUCT PORTFOLIO
  • TABLE 83. PACIFIC BIOSCIENCES OF CALIFORNIA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. ROCHE: KEY EXECUTIVES
  • TABLE 85. ROCHE: COMPANY SNAPSHOT
  • TABLE 86. ROCHE: OPERATING SEGMENTS
  • TABLE 87. ROCHE: PRODUCT PORTFOLIO
  • TABLE 88. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. NEUANALYTICA CORP: KEY EXECUTIVES
  • TABLE 90. NEUANALYTICA CORP: COMPANY SNAPSHOT
  • TABLE 91. NEUANALYTICA CORP: OPERATING SEGMENTS
  • TABLE 92. NEUANALYTICA CORP: PRODUCT PORTFOLIO
  • TABLE 93. NEUANALYTICA CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PRENATAL DNA SEQUENCING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PRENATAL DNA SEQUENCING MARKET
  • FIGURE 3. SEGMENTATION PRENATAL DNA SEQUENCING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PRENATAL DNA SEQUENCING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPRENATAL DNA SEQUENCING MARKET
  • FIGURE 11. PRENATAL DNA SEQUENCING MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 12. PRENATAL DNA SEQUENCING MARKET FOR HEMOPHILIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PRENATAL DNA SEQUENCING MARKET FOR DOWN SYNDROME, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. PRENATAL DNA SEQUENCING MARKET FOR CYSTIC FIBROSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. PRENATAL DNA SEQUENCING MARKET FOR AUTISM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. PRENATAL DNA SEQUENCING MARKET FOR DIGEORGE SYNDROME, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. PRENATAL DNA SEQUENCING MARKET FOR AIDS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. PRENATAL DNA SEQUENCING MARKET FOR CANCER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. PRENATAL DNA SEQUENCING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: PRENATAL DNA SEQUENCING MARKET
  • FIGURE 26. TOP PLAYER POSITIONING, 2024
  • FIGURE 27. ILLUMINA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. ILLUMINA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. ILLUMINA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. BGI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. BGI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. BGI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. OXFORD NANOPORE TECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. OXFORD NANOPORE TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. OXFORD NANOPORE TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. PERKINELMER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. PERKINELMER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. PERKINELMER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. QIAGEN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. QIAGEN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. QIAGEN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. AGILENT TECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. AGILENT TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. AGILENT TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. PACIFIC BIOSCIENCES OF CALIFORNIA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. PACIFIC BIOSCIENCES OF CALIFORNIA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. PACIFIC BIOSCIENCES OF CALIFORNIA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. ROCHE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. ROCHE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. ROCHE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. NEUANALYTICA CORP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. NEUANALYTICA CORP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. NEUANALYTICA CORP: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Prenatal DNA Sequencing Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved